fibroblast growth factor 1

Brain-derived acidic fibroblast growth factor (brain-derived aFGF) (1-11) is a peptide fragment of brain-derived aFGF. Brain-derived aFGF is an angiogenic vascular endothelial cell mitogen produced in bovine brain that has sequence homology to interleukin-1. aFGF (1-11) corresponds to amino acid residues 1-11 of the full length peptide.

Brain-derived basic fibroblast growth factor (1-24) (brain-derived bFGF) is a peptide fragment of brain-derived bFGF. bFGF is a peptide produced in bovine brain that is protective in a rat model of pressure-induced retinal ischemia. bFGF (1-24) corresponds to amino acid residues 1-24 of the full length peptide.

Brain Derived Basic Fibroblast Growth Factor (1-24) (FGF basic 1-24), a synthetic peptide with anti-bacterial and anti-HBV properties, is utilized in infectious and immune disease research [1].

Regorafenib (BAY 73-4506) is an orally active, multi-targeted receptor tyrosine kinase inhibitor that inhibits RET, C-RAF, VEGFR2, c-Kit, VEGFR1, and PDGFRβ, exhibiting both antitumor and anti-angiogenic activity.

SU4984 is a cell-permeable, ATP-competitive and reversible inhibitor of the fibroblast growth factor receptor 1 (FGFR1).

FGFR1/DDR2 inhibitor 1 is an inhibitor of discoidin domain receptor 2 (DDR2) and fibroblast growth factor receptor 1 (FGFR1), with IC50 values of 31.1 nM, 108.4 nM, and 3.2 nM for FGFR1, KG-1, and DDR2, respectively.

Rogaratinib (BAY1163877) is an aberrant inhibitor of fibroblast growth factor receptor (FGFR). Rogaratinib is as an orally available, selective and potent inhibitor of FGFR-1, -2 and -3 kinase activity.

BW710 is an orally active inhibitor specifically targeting fibroblast growth factor receptor 2 (FGFR2). It effectively inhibits the proliferation of BaF3-FGFR2 cells with an IC50 value of 2.8 nM. BW710 completely suppresses FGFR2 enzymatic activity and demonstrates selectivity among 75 tyrosine kinases, including FGFR1, FGFR3, and FGFR4, at a 1 μM concentration. Additionally, BW710 impedes FGFR2 signaling and selectively inhibits the proliferation of cancer cells driven by FGFR2. It exhibits promising pharmacokinetic properties, with an oral bioavailability of 29% in mice.

Sirtuinmodulator 8 is a modulator of silent information regulator proteins (sirtuins) that activates their activity. It significantly reduces the expression of monocyte chemoattractant protein-1 (MCP-1) while enhancing the expression of fibroblast growth factor 21 (FGF21). Sirtuinmodulator 8 regulates the expression of genes related to inflammation and metabolism, showing potential for research into metabolic diseases [such as diabetes and obesity] and inflammatory diseases.

PD-161570 is a potent and ATP-competitive human FGF-1 receptor inhibitor with an IC50 of 39.9 nM and a Ki of 42 nM. It also inhibits the PDGFR, EGFR, and c-Src tyrosine kinases with IC50 values of 310 nM, 240 nM, and 44 nM, respectively.

NP603 is a highly potent fibroblast growth factor receptor 1 (FGFR1) inhibitor that significantly inhibits rhFGF‑2-induced proliferation of human umbilical vein endothelial cells (HUVECs), with a minimum effective dose of 0.4 μM.

AS1069562 is an inhibitor of serotonin (5-HT) and norepinephrine (NE) reuptake which acts by notably restoring reduced insulin-like growth factor 1 and fibroblast growth factor 2 mRNA levels in dorsal root ganglion and spinal cord, respectively.

FIIN-3, an irreversible inhibitor of FGFR (Fibroblast Growth Factor Receptor), is a chemical compound designed to bind permanently to FGFR, thereby inhibiting its activity and potential downstream signaling pathways.

PRLX-93936 is a selective Ras pathway protein inhibitor that modulates RAS/JNK pathway-associated protein phosphorylation, induces caspase-dependent apoptosis and cell cycle arrest, and exhibits anticancer activity.

Brain-derived acidic fibroblast growth factor (102-111) is a peptide fragment of brain-derived acidic fibroblast growth factor (aFGF). aFGF is an angiogenic vascular endothelial cell mitogen produced in bovine brain that has sequence homology to interleukin-1. It also shares sequence homology with the known neuropeptides neuromedin C , bombesin , neuromedin K , substance K , substance P , physalaemin, and eledoisin. aFGF (102-111) corresponds to amino acid residues 102-111 of the fulllength peptide.

Picropodophyllotoxin (AXL 1717) is a cyclolignan alkaloid found in the mayapple plant family (Podophyllum peltatum), and a small molecule inhibitor of the insulin-like growth factor 1 receptor (IGF1R) with potential antineoplastic activity. Picropodophyllotoxin (AXL 1717) specifically inhibits the activity and downregulates the cellular expression of IGF1R without interfering with activities of other growth factor receptors, such as receptors for insulin, epidermal growth factor, platelet-derived growth factor, fibroblast growth factor and mast/stem cell growth factor (KIT). This agent shows potent activity in the suppression o f tumor cell proliferation and the induction of tumor cell apoptosis. IGF1R, a receptor tyrosine kinase overexpressed in a variety of human cancers, plays a critical role in the growth and survival of many types of cancer cells.

Ferulic acid acyl-β-D-glucoside, a metabolite of Ferulic Acid, is a novel inhibitor of fibroblast growth factor receptor 1 (FGFR1). It exhibits IC50 values of 3.78 µM and 12.5 µM for FGFR1 and FGFR2, respectively.

Futibatinib (TAS-120) is an orally active, potent, selective, highly bioavailable, and irreversible FGFR inhibitor with IC50 values ​​of 3.9, 1.3, 1.6, and 8.3 nM for FGFR1, FGFR2, FGFR3, and FGFR4, respectively. [2]

Tyrosine kinase-IN-1 is a multi-targeted tyrosine kinase inhibitor that acts on KDR, Flt-1, FGFR1, and PDGFRα with IC50 values of 4 nM, 20 nM, 4 nM, and 2 nM, respectively.

FGFR-IN-3 (compound 6) is a highly potent, orally active modulator of FGFR (fibroblast growth factor receptor) with the ability to penetrate the blood-brain barrier (BBB). It exhibits significant neuroprotective properties, making it a promising candidate for research on neurodegenerative diseases [1].

SUN13837 is an orally active, potent modulator of the fibroblast growth factor receptor (FGFR) capable of penetrating the blood-brain barrier (BBB). It exhibits neuroprotective activity and holds promise for advancing research on neurodegenerative diseases [1].

CPL304110 is an orally active, selective and potent inhibitor of the fibroblast growth factor receptor FGFR (1-3), acting on FGFR1 (IC50: 0.75 nM), FGFR2 (IC50: 0.5 nM), FGFR3 (IC50: 3.05 nM).

Dovitinib is an orally active, multi-targeted tyrosine kinase (RTK) inhibitor with anti-tumor effects.

FGFR3-IN-1 (compound 1) is a fibroblast growth factor receptor (FGFR) inhibitor that targets FGFR1 (IC50: 40 nM), FGFR2 (IC50: 5.1 nM), and FGFR3 (IC50: 12 nM).